Kyowa Kirin to Acquire Orchard Therapeutics

 -Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases-

-Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)-
-Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million-
-Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST-

https://www.globenewswire.com/news-release/2023/10/05/2755103/0/en/Kyowa-Kirin-to-Acquire-Orchard-Therapeutics.html